avigation
olchemim Phytohormone standards CYTOKININS
發布時間：2024-06-13
訪問次數：1910
公司地址：廣州市天河區天河北路僑林街47號中旅商務大廈東塔25E
產品價格：來電咨詢
The natural cytokinins are adenine derivatives bearing isoprenoid (zeatin, dihydrozeatin, isopentenyladenine) or aromatic (kinetin, benzyladenine, topolin) N6-side chain. Phenylureas (thidiazuron) and others are synthetic cytokinins. Cytokinins were recognized because of their ability to induce cell division in the presence of auxin but they are also involved in initiation of shoot primordia, in solute mobilization and cell senescence.
ADENINE (Ade) [6-aminopurine]
| MW 135.13; crystalline; purity > 98% (HPLC) | ||
| R:22, S:26, 36; CAS:73-24-5; C5H5N5 | ||
![ADENINE (Ade) [6-aminopurine]](http://www.olchemim.cz/img/001/001_024.jpg) | ||
| 001 0241 | 5 | g |
| 001 0242 | 25 | g |
| 001 0243 | 100 | g |
| 001 0244 | 500 | g |
ADENINE HYDROCHLORIDE (Ade.HCl) [6-aminopurine hydrochloride]
| MW 171.59; crystalline; purity > 98% (HPLC) | ||
| R:22, S:26, 36; CAS: 2922-28-3; C5H5N5.HCl | ||
| water soluble | ||
 | ||
| 001 3261 | 5 | g |
| 001 3262 | 25 | g |
| 001 3263 | 100 | g |
ADENINE HEMISULFATE (Ade.1/2H2SO4) [6-aminopurine hemisulfate]
| MW 184.17; crystalline; purity > 98% (HPLC) | ||
| S:26, 36; CAS: 321-30-2; C5H5N5.1/2H2SO4 | ||
 | ||
| 001 3271 | 5 | g |
| 001 3272 | 25 | g |
| 001 3273 | 100 | g |
ADENOSINE (Ado) [6-amino-9-β-D-ribofuranosylpurine]
| MW 267.25; crystalline; purity > 98% (HPLC) | ||
| S:26, 36; CAS: 58-61-7; C10H13N5O4 | ||
 | ||
| 001 6301 | 5 | g |
| 001 6302 | 25 | g |
| 001 6303 | 100 | g |
| 001 6304 | 500 | g |
N6-BENZYLADENINE (BA) [6 - benzylaminopurine]
| MW 225.25; crystalline; purity > 98% (HPLC) | ||
| R:36/37/38, S:26, 36; CAS: 1214-39-7; C12H11N5 | ||
 | ||
| 001 0221 | 1 | g |
| 001 0222 | 5 | g |
| 001 0223 | 25 | g |
| 001 0224 | 100 | g |
N6-BENZYLADENINE HYDROCHLORIDE (BA.HCl) [6 - benzylaminopurine hydrochloride]
| MW 261.71; crystalline; purity > 98% (HPLC) | ||
| R:36/37/38, S:26, 36; CAS: 162714-86-5; C12H11N5.HCl | ||
| water soluble | ||
 | ||
| 001 0181 | 250 | mg |
| 001 0182 | 1 | g |
| 001 0183 | 5 | g |
N6-BENZYLADENOSINE (BAR) [6-benzylamino-9-β-D-ribofuranosylpurine]
| MW 357.37; crystalline; purity > 98% (HPLC) | ||
| S:26, 36; CAS: 4294-16-0; C17H19N5O4 | ||
 | ||
| 001 0551 | 100 | mg |
| 001 0552 | 250 | mg |
| 001 0553 | 1 | g |
| 001 0554 | 5 | g |
N6-BENZYLADENINE-3-GLUCOSIDE (BA3G) [6-benzylamino-3-β-D-glucopyranosylpurine]
| MW 387.40; crystalline; purity > 95% (HPLC ) | ||
| S:26, 36; CAS: 56159-41-2; C18H21N5O5 | ||
 | ||
| 001 0581 | 1 | mg |
| 001 0582 | 2 | mg |
| 001 0583 | 5 | mg |
N6-BENZYLADENINE-7-GLUCOSIDE (BA7G) [6-benzylamino-7-β-D-glucopyranosylpurine]
| MW 387.40; crystalline; purity > 95% (HPLC ) | ||
| S:26, 36; CAS: 56159-42-3; C18H21N5O5 | ||
 | ||
| 001 0571 | 1 | mg |
| 001 0572 | 2 | mg |
| 001 0573 | 5 | mg |
N6-BENZYLADENINE-9-GLUCOSIDE (BA9G) [6-benzylamino-9-β-D-glucopyranosylpurine]
| MW 387.40; crystalline; purity > 95% (HPLC ) | ||
| R: 36/37/38, S: 26, 36; CAS: 4294-17-1; C18H21N5O5 | ||
 | ||
| 001 3281 | 1 | mg |
| 001 3282 | 2 | mg |
| 001 3283 | 5 | mg |
N6-BENZYL-9-(2-TETRAHYDROPYRANYL)ADENINE (BPA)
| MW 309.37; crystalline; purity > 98% (HPLC ) | ||
| R:22, S: 26,36; CAS: 2312-73-4; C17H19N5O | ||
 | ||
| 001 3291 | 100 | mg |
| 001 3292 | 500 | mg |
| 001 3293 | 1 | g |
| 001 3294 | 5 | g |
| 001 3295 | 25 | g |
N6 - BENZYLADENOSINE-5'-MONOPHOSPHATE SODIUM SALT (BAMP) [6-benzylamino-9-β-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]
| MW 499.34; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 13484-66-7; C17H18N5Na2O7P.H2O | ||
 | ||
| 001 5001 | 1 | mg |
| 001 5002 | 2 | mg |
| 001 5003 | 5 | mg |
N-(2-CHLORO-4-PYRIDYL)-N'-PHENYLUREA (CPPU,4-CPPU)
| MW 247.69; crystalline; purity > 98% (HPLC) | ||
| R:36/37, S: 26, 36; CAS: 68157-60-8; C10H12ClN3O | ||
 | ||
| 001 0191 | 100 | mg |
| 001 0192 | 250 | mg |
| 001 0193 | 1 | g |
N6 - CYCLOPENTYLADENOSINE-5'-MONOPHOSPHATE SODIUM SALT (MP) [6-cyclopentylamino-9-β-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]
| MW 459.31; CRYSTALLINE; purity > 97% (HPLC) | ||
| S:26, 36; CAS: 117778-38-8; C15H20N5Na2O7P.H2O | ||
 | ||
| 001 6261 | 1 | mg |
| 001 6262 | 2 | mg |
| 001 6263 | 5 | mg |
DIHYDROZEATIN (DZ) [6-(4-hydroxy-3-methylbutylamino)purine]
| MW 221.26; crystalline; purity > 99% (HPLC) | ||
| S:26, 36; CAS: 14894-18-9; C10H15N5O | ||
 | ||
| 001 0601 | 5 | mg |
| 001 0602 | 10 | mg |
| 001 0603 | 50 | mg |
| 001 0604 | 250 | mg |
| 001 0605 | 1 | g |
DIHYDROZEATIN HYDROCHLORIDE (DZ.HCl) [6-(4-hydroxy-3-methylbutylamino)purine hydrochloride]
| MW 257.72; crystalline; purity > 98% (HPLC) | ||
| R:22, S:26, 36; CAS: 1402800-82-1; C10H15N5O.HCl | ||
| water soluble | ||
 | ||
| 001 0251 | 10 | mg |
| 001 0252 | 50 | mg |
| 001 0253 | 250 | mg |
DIHYDROZEATIN RIBOSIDE (DZR) [6-(4-hydroxy-3-methylbutylamino)-9-β-D-ribofuranosylpurine]
| MW 353.38; crystalline; purity > 98% (HPLC) | ||
| S:26, 36; CAS: 22663-55-4; C15H23N5O5 | ||
 | ||
| 001 0611 | 5 | mg |
| 001 0612 | 10 | mg |
| 001 0613 | 50 | mg |
| 001 0614 | 250 | mg |
| 001 0615 | 1 | g |
DIHYDROZEATIN-7-GLUCOSIDE (DZ7G) [6-(4-hydroxy-3-methylbutylamino)-7-β-D-glucopyranosylpurine]
| MW 383.41; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 91599-03-0; C16H25N5O6 | ||
 | ||
| 001 0621 | 1 | mg |
| 001 0622 | 2 | mg |
| 001 0623 | 5 | mg |
DIHYDROZEATIN-9-GLUCOSIDE (DZ9G) [6-(4-hydroxy-3-methylbutylamino)-9-β-D-glucopyranosylpurine]
| MW 383.41; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 73263-99-7; C16H25N5O6 | ||
 | ||
| 001 0631 | 1 | mg |
| 001 0632 | 2 | mg |
| 001 0633 | 5 | mg |
DIHYDROZEATIN-O-GLUCOSIDE (DZOG) [6-(4-β-D-glucopyranosyloxy-3-methylbytylamino)purine]
| MW 383.41; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 62512-96-3; C16H25N5O6 | ||
 | ||
| 001 0641 | 1 | mg |
| 001 0642 | 2 | mg |
| 001 0643 | 5 | mg |
DIHYDROZEATIN-O-GLUCOSIDE RIBOSIDE (DZROG) [6-(4-β-D-glucopyranosyloxy-3-methylbutyl)amino-9-β-D-purine ribofuranosyl]
| MW 515.52; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 62512-95-2; C21H33N5O10 | ||
 | ||
| 001 0651 | 1 | mg |
| 001 0652 | 2 | mg |
| 001 0653 | 5 | mg |
DIHYDROZEATIN RIBOSIDE-5'-MONOPHOSPHATE SODIUM SALT (DZRMP) [6-(4-hydroxy-3-methylbutylamino)-9-β-D-ribofuranosyl purine-5'-monophosphate disodium monohydrate]
| MW 495.34; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 31284-94-3; C15H22N5Na2O8P.H2O | ||
 | ||
| 001 5011 | 1 | mg |
| 001 5012 | 2 | mg |
| 001 5013 | 5 | mg |
DIHYDROZEATIN-O-ACETYL (AcDZ) [6-(4-acetoxy-3-methylbutylamino)purine]
| MW 263.30; crystalline; purity > 98% (HPLC) | ||
| S:26, 36; CAS: 126221-88-3; C12H17N5O2 | ||
 | ||
| 001 5021 | 5 | mg |
| 001 5022 | 10 | mg |
| 001 5023 | 50 | mg |
N6-(3-FLUOROBENZYL)ADENINE (mFBA) [6 - (3-fluorobenzylamino)purine]
| MW 243.25; crystalline; purity > 98% (HPLC) | ||
| S:26, 36; CAS: 525608-36-0; C12H10FN5 | ||
 | ||
| 001 5801 | 100 | mg |
| 001 5802 | 500 | mg |
| 001 5803 | 1 | g |
N6-(3-FLUOROBENZYL)ADENOSINE (mFBAR)[6-(3-fluorobenzylamino)-9-β-D-ribofuranosylpurine]
| MW 375.36; crystalline; purity > 98% (HPLC) | ||
| S:26, 36; CAS: 29204-64-6; C17H18FN5O4 | ||
 | ||
| 001 5811 | 100 | mg |
| 001 5812 | 500 | mg |
| 001 5813 | 1 | g |
| 001 5814 | 5 | g |
HYPOXANTHINE (Hyp) [6-hydroxypurine]
| MW 136.11; crystalline; purity > 98% ( HPLC ) | ||
| S:26, 36; CAS: 68-94-0; C5H4N4O | ||
 | ||
| 001 5941 | 5 | g |
| 001 5942 | 25 | g |
| 001 5943 | 100 | g |
N6-ISOPENTENYLADENINE (iP) [6-(3,3-dimethylallylamino)purine]
| MW 203.25; crystalline; purity > 99% (HPLC) | ||
| S:26, 36; CAS: 2365-40-4; C10H13N5 | ||
 | ||
| 001 0161 | 1 | g |
| 001 0162 | 5 | g |
| 001 0163 | 10 | g |
| 001 0164 | 25 | g |
N6-ISOPENTENYLADENINE HYDROCHLORIDE (iP.HCl) [6-(3,3-dimethylallylamino)purine hydrochloride]
| MW 239.71; crystalline; purity > 98% (HPLC) | ||
| R:22, S:26, 36; CAS: 177966-67-5; C10H13N5.HCl | ||
| water soluble | ||
 | ||
| 001 5031 | 1 | g |
| 001 5032 | 5 | g |
| 001 5033 | 10 | g |
N6-ISOPENTENYLADENOSINE (iPR) [6-(3,3-dimethylallylamino)-9-β-D-ribofuranosylpurine]
| MW 335.37; crystalline; purity > 99% (HPLC) | ||
| S:26, 36; CAS: 7724-76-7; C15H21N5O4 | ||
 | ||
| 001 0171 | 100 | mg |
| 001 0172 | 250 | mg |
| 001 0173 | 1 | g |
2-BENZYLTHIO-N6-ISOPENTENYLADENINE (2BSiP)[2-benzylthio-6-(3,3-dimethylallylamino)purine]
| MW 325.44; crystalline; purity > 98% (HPLC) | ||
| S:26, 36; CAS: 52172-11-9; C17H19N5S | ||
 | ||
| 001 5241 | 5 | mg |
| 001 5242 | 10 | mg |
| 001 5243 | 50 | mg |
2-METHYLTHIO-N6-ISOPENTENYLADENINE (2MeSiP) [2-methylthio-6-(3,3-dimethylallylamino)purine]
| MW 249.34; crystalline; purity > 98% (HPLC) | ||
| S:23, 36; CAS: 20758-33-2; C11H15N5S | ||
 | ||
| 001 5071 | 1 | mg |
| 001 5072 | 2 | mg |
| 001 5073 | 5 | mg |
2-METHYLTHIO-N6-ISOPENTENYLADENOSINE (2MeSiPR) [2-methylthio-6-(3,3-dimethylallylamino)-9-β-D-ribofuranosylpurine]
| MW 381.46; CRYSTALLINE; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 20859-00-1; C16H23N5O4S | ||
 | ||
| 001 5061 | 1 | mg |
| 001 5062 | 2 | mg |
| 001 5063 | 5 | mg |
2-MERCAPTO-N6-ISOPENTENYLADENINE (2SiP) [2-mercapto-6-(3,3-dimethylallylamino)purine]
| MW 235.31; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 52172-12-0; C10H13N5S | ||
 | ||
| 001 5081 | 1 | mg |
| 001 5082 | 2 | mg |
| 001 5083 | 5 | mg |
N6-ISOPENTENYLADENINE-3-GLUCURONIDE (iP3GN)
| MW 379.38; CRYSTALLINE; purity > 97% (HPLC) | ||
| S:26, 36; CAS: 147663-48-7; C16H21N5O6 | ||
 | ||
| 001 5981 | 5 | mg |
| 001 5982 | 25 | mg |
| 001 5983 | 50 | mg |
N6-ISOPENTENYLADENINE-3-GLUCURONIDE amide (iP3GNA)
| MW 378.39; CRYSTALLINE; purity > 98% (HPLC) | ||
| S:26, 36; CAS: NONE; C16H22N6O5 | ||
 | ||
| 001 5991 | 5 | mg |
| 001 5992 | 25 | mg |
| 001 5993 | 50 | mg |
N6-ISOPENTENYLADENOSINE-5'-MONOPHOSPHATE SODIUM SALT (iPMP) [6-(3,3-dimethylallylamino)-9-b-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]
| MW 477.33; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 20268-93-3; C15H20N5Na2O7P.H2O | ||
 | ||
| 001 5041 | 1 | mg |
| 001 5042 | 2 | mg |
| 001 5043 | 5 | mg |
N6-ISOPENTENYLADENINE-7-GLUCOSIDE (iP7G) [6-(3,3-dimethylallylamino)-7-β-D-glucopyranosylpurine]
| MW 365.39; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 59384-58-6; C16H23N5O5 | ||
 | ||
| 001 5051 | 1 | mg |
| 001 5052 | 2 | mg |
| 001 5053 | 5 | mg |
N6-ISOPENTENYLADENINE-9-GLUCOSIDE (iP9G) [6-(3,3-dimethylallylamino)-9-β-D-glucopyranosylpurine]
| MW 365.39; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 83087-94-9; C16H23N5O5 | ||
 | ||
| 001 0231 | 1 | mg |
| 001 0232 | 2 | mg |
| 001 0233 | 5 | mg |
KINETIN (K) [6-furfurylaminopurine]
| MW 215.22; crystalline; purity > 99% (HPLC) | ||
| S:26, 36; CAS: 525-79-1; C10H9N5O | ||
 | ||
| 001 0341 | 250 | mg |
| 001 0342 | 1 | g |
| 001 0343 | 5 | g |
| 001 0344 | 25 | g |
KINETIN HYDROCHLORIDE(K.HCl) [6-furfurylaminopurine hydrochloride]
| MW 251.68; crystalline; purity > 98% (HPLC) | ||
| R:22, S:26, 36; CAS: 177966-68-6; C10H9N5O.HCl | ||
| water soluble | ||
 | ||
| 001 0261 | 100 | mg |
| 001 0262 | 500 | mg |
| 001 0263 | 1 | g |
KINETIN RIBOSIDE (KR) [6 - furfurylamino-9-b-D-ribofuranosylpurine]
| MW 347.33; crystalline; purity > 99% (HPLC) | ||
| S:26, 36; CAS: 4338-47-0; C15H17N5O5 | ||
 | ||
| 001 0351 | 100 | mg |
| 001 0352 | 250 | mg |
| 001 0353 | 1 | g |
| 001 0354 | 5 | g |
KINETIN-3-GLUCOSIDE (αK3G) [6-furfurylamino-3-α-D-glucopyranosylpurine]
| MW 377.36; crystalline; purity > 95% (HPLC ) | ||
| S:26, 36; CAS: 900786-14-3; C16H19N5O6 | ||
 | ||
| 001 5771 | 1 | mg |
| 001 5772 | 2 | mg |
| 001 5773 | 5 | mg |
KINETIN-9-GLUCOSIDE (K9G) [6-furfurylamino-9-β-D-glucopyranosylpurine]
| MW 377.36; crystalline; purity > 95% (HPLC ) | ||
| S:26, 36; CAS: 98177-43-6; C16H19N5O6 | ||
 | ||
| 001 0441 | 1 | mg |
| 001 0442 | 2 | mg |
| 001 0443 | 5 | mg |
KINETIN RIBOSIDE-5'-MONOPHOSPHATE SODIUM SALT (KMP) [6-furfurylamino-9-β-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]
| MW 489.30; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 13484-67-8; C15H16N5Na2O8P.H2O | ||
 | ||
| 001 5091 | 1 | mg |
| 001 5092 | 2 | mg |
| 001 5093 | 5 | mg |
PHENYLADENINE [6-phenylaminopurine, 6-anilinopurine]
| MW 211.23; crystalline; purity > 95% (HPLC) | ||
| R:36/37/38; S:26, 36; CAS:1210-66-8; C11H9N5 | ||
![PHENYLADENINE [6-phenylaminopurine, 6-anilinopurine]](http://www.olchemim.cz/img/001/001_697.jpg) | ||
| 001 6971 | 100 | mg |
| 001 6972 | 500 | mg |
| 001 6973 | 1 | g |
| MSDS | ||
THIDIAZURON (TDZ) [N-phenyl-N'-(1,2,3-thiadiazol-5-yl)urea]
| MW 220.25; crystalline; purity > 98% (HPLC ) | ||
| R:36/37/38, S:22, 26, 36; CAS: 51707-55-2; C9H8N4OS | ||
 | ||
| 001 3161 | 5 | mg |
| 001 3162 | 25 | mg |
| 001 3163 | 250 | mg |
| 001 3164 | 1 | g |
| 001 3165 | 5 | g |
meta-TOPOLIN (mT) [6-(3-hydroxybenzylamino)purine]
| MW 241.25; crystalline; purity >99% (HPLC) | ||
| S:26, 36; CAS: 75737-38-1; C12H11N5O | ||
 | ||
| 001 0101 | 100 | mg |
| 001 0102 | 500 | mg |
| 001 0103 | 1 | g |
| 001 0104 | 5 | g |
| 001 0105 | 25 | g |
meta-TOPOLIN RIBOSIDE (mTR) [6-(3-hydroxybenzylamino)-9-b-D-ribofuranosylpurine]
| MW 373.37; crystalline;purity >99% (HPLC) | ||
| S:26, 36; CAS: 110505-76-5; C17H19N5O5 | ||
 | ||
| 001 0111 | 100 | mg |
| 001 0112 | 500 | mg |
| 001 0113 | 1 | g |
meta-TOPOLIN-9-GLUCOSIDE (mT9G) [6-(3-hydroxybenzylamino)-9-β-D-glucopyranosylpurine]
| MW 403.40; crystalline; purity >95% (HPLC) | ||
| S:26, 36; CAS: 179528-30-4; C18H21N5O6 | ||
 | ||
| 001 0141 | 1 | mg |
| 001 0142 | 2 | mg |
| 001 0143 | 5 | mg |
meta-TOPOLIN RIBOSIDE-5'-MONOPHOSPHATE SODIUM SALT (mTMP) [6-(3-hydroxybenzylamino)-9-β-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]
| MW 515.34; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 946853-27-6; C17H18N5Na2O8P.H2O | ||
 | ||
| 001 6841 | 1 | mg |
| 001 6842 | 2 | mg |
| 001 6843 | 5 | mg |
ortho-TOPOLIN (oT) [6-(2-hydroxybenzylamino)purine]
| MW 241.25; crystalline; purity > 99% (HPLC) | ||
| S:26, 36; CAS: 20366-83-0; C12H11N5O | ||
 | ||
| 001 0121 | 100 | mg |
| 001 0122 | 500 | mg |
| 001 0123 | 1 | g |
ortho-TOPOLIN RIBOSIDE (oTR)[6-(2-hydroxybenzylamino)-9-b-D-ribofuranosylpurine]
| MW 373.37; crystalline; purity > 99% (HPLC) | ||
| S:26, 36; CAS: 50868-58-1; C17H19N5O5 | ||
 | ||
| 001 0131 | 100 | mg |
| 001 0132 | 500 | mg |
| 001 0133 | 1 | g |
ortho-TOPOLIN-9-GLUCOSIDE (oT9G) [6-(2-hydroxybenzylamino)-9-β-D-glucopyranosylpurine]
| MW 403.40; crystalline; purity >95% (HPLC) | ||
| S:26, 36; CAS: 160299-96-7; C18H21N5O6 | ||
 | ||
| 001 0151 | 1 | mg |
| 001 0152 | 2 | mg |
| 001 0153 | 5 | mg |
ortho-TOPOLIN RIBOSIDE-5'-MONOPHOSPHATE SODIUM SALT (oTMP) [6-(2-hydroxybenzylamino)-9-β-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]
| MW 515.34; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 1242061-01-3; C17H18N5Na2O8P.H2O | ||
 | ||
| 001 6831 | 1 | mg |
| 001 6832 | 2 | mg |
| 001 6833 | 5 | mg |
para-TOPOLIN (pT) [6-(4-hydroxybenzylamino)purine]
| MW 241.25; crystalline; purity > 99% (HPLC) | ||
| S:26, 36; CAS: 80054-30-4; C12H11N5O | ||
 | ||
| 001 0451 | 100 | mg |
| 001 0452 | 500 | mg |
| 001 0453 | 1 | g |
para-TOPOLIN RIBOSIDE (pTR) [6-(4-hydroxybenzylamino)-9-b-D-ribofuranosylpurine]
| MW 373.37; crystalline; purity > 99% (HPLC) | ||
| S:26, 36; CAS: 23666-24-2; C17H19N5O5 | ||
 | ||
| 001 0461 | 100 | mg |
| 001 0462 | 500 | mg |
| 001 0463 | 1 | g |
para-TOPOLIN-9-GLUCOSIDE (pT9G) [6-(4-hydroxybenzylamino)-9-β-D-glucopyranosylpurine]
| MW 403.40; crystalline; purity >95% (HPLC) | ||
| S:26, 36; CAS: 1046433-04-8; C18H21N5O6 | ||
 | ||
| 001 0401 | 1 | mg |
| 001 0402 | 2 | mg |
| 001 0403 | 5 | mg |
para-TOPOLIN RIBOSIDE-5'-MONOPHOSPHATE SODIUM SALT (pTMP) [6-(3-hydroxybenzylamino)-9-β-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]
| MW 515.34; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 1402800-77-4; C17H18N5Na2O8P.H2O | ||
 | ||
| 001 6851 | 1 | mg |
| 001 6852 | 2 | mg |
| 001 6853 | 5 | mg |
ortho-METHOXYTOPOLIN (MeoT) [6-(2-methoxybenzylamino)purine]
| MW 255.28; crystalline; purity > 99% (HPLC) | ||
| S:26, 36; CAS: 75737-41-6; C13H13N5O | ||
 | ||
| 001 0491 | 100 | mg |
| 001 0492 | 500 | mg |
| 001 0493 | 1 | g |
ortho-METHOXYTOPOLIN RIBOSIDE (MeoTR) [6-(2-methoxybenzylamino)-9-β-D-ribofuranosylpurine]
| MW 387.40; crystalline; purity > 99% (HPLC) | ||
| S:26, 36; CAS: 23660-98-2; C18H21N5O5 | ||
 | ||
| 001 0501 | 100 | mg |
| 001 0502 | 500 | mg |
| 001 0503 | 1 | g |
ortho-METHOXYTOPOLIN-9-GLUCOSIDE (MeoT9G) [6-(2-methoxybenzylamino)-9-β-D-glucopyranosylpurine]
| MW 417.43; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 1226978-27-7; C19H23N5O6 | ||
 | ||
| 001 5861 | 1 | mg |
| 001 5862 | 2 | mg |
| 001 5863 | 5 | mg |
meta-METHOXYTOPOLIN (MemT) [6-(3-methoxybenzylamino)purine]
| MW 255.28; crystalline; purity > 99% (HPLC) | ||
| S:26, 36; CAS: 75737-39-2; C13H13N5O | ||
 | ||
| 001 0511 | 100 | mg |
| 001 0512 | 500 | mg |
| 001 0513 | 1 | g |
meta-METHOXYTOPOLIN RIBOSIDE (MemTR) [6-(3-methoxybenzylamino)-9-β-D-ribofuranosylpurine]
| MW 387.40; crystalline; purity > 99% (HPLC) | ||
| S:26, 36; CAS: 101565-95-1; C18H21N5O5 | ||
 | ||
| 001 0531 | 100 | mg |
| 001 0532 | 500 | mg |
| 001 0533 | 1 | g |
meta-METHOXYTOPOLIN-9-GLUCOSIDE (MeoT9G) [6-(3-methoxybenzylamino)-9-β-D-glucopyranosylpurine]
| MW 417.43; crystallinE; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 1226978-27-7; C19H23N5O6 | ||
 | ||
| 001 5871 | 1 | mg |
| 001 5872 | 2 | mg |
| 001 5873 | 5 | mg |
para-METHOXYTOPOLIN-9-GLUCOSIDE (MeoT9G) [6-(4-methoxybenzylamino)-9-β-D-glucopyranosylpurine]
| MW 417.43; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: NONE; C19H23N5O6 | ||
 | ||
| 001 5881 | 1 | mg |
| 001 5882 | 2 | mg |
| 001 5883 | 5 | mg |
trans-ZEATIN (tZ) [6-((E)-4-hydroxy-3-methylbut-2-enylamino)purine]
| MW 219.25; crystalline; purity > 99% (HPLC); white crystalls; cis-isomer < 0.05% | ||
| S:26, 36; CAS: 1637-39-4; C10H13N5O | ||
 | ||
| 001 0301 | 5 | mg |
| 001 0302 | 10 | mg |
| 001 0303 | 100 | mg |
| 001 0304 | 1 | g |
trans-ZEATIN HYDROCHLORIDE (tZ.HCl) [6-((E)-4-hydroxy-3-methylbut-2-enylamino)purine hydrochloride]
| MW 255.71; crystalline; purity > 97% (HPLC) | ||
| R:22, S:36; CAS: 6025-81-6; C10H13N5O.HCl | ||
| water soluble | ||
 | ||
| 001 5101 | 100 | mg |
| 001 5102 | 250 | mg |
| 001 5103 | 1 | g |
trans-ZEATIN RIBOSIDE (tZR) [6-((E)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine]
| MW 351.37; crystalline; purity > 99% (HPLC); white crystalls; cis-isomer < 0.05% | ||
| S:26, 36; CAS: 6025-53-2; C15H21N5O5 | ||
 | ||
| 001 0311 | 5 | mg |
| 001 0312 | 10 | mg |
| 001 0313 | 100 | mg |
| 001 0314 | 1 | g |
ZEATIN mixed isomers (E/Z) equal mixture of cis- and trans- isomers [6-(4-hydroxy-3-methylbut-2-enylamino)purine]
| MW 219.25; crystalline; purity > 98% (HPLC) | ||
| S:26, 36; CAS: 13114-27-7; C10H13N5O | ||
 | ||
| 001 3171 | 5 | mg |
| 001 3172 | 10 | mg |
| 001 3173 | 100 | mg |
| 001 3174 | 1 | g |
ZEATIN RIBOSIDE mixed isomers (E/Z) equal mixture of cis- and trans- isomers [6-(4-hydroxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine]
| MW 351.37; crystalline; purity > 98% (HPLC) | ||
| S:26, 36; CAS: 28542-78-1; C15H21N5O5 | ||
| ||
| 001 3181 | 5 | mg |
| 001 3182 | 10 | mg |
| 001 3183 | 100 | mg |
| 001 3184 | 1 | g |
trans-ZEATIN-7-GLUCOSIDE (tZ7G) [6-((E)-4-hydroxy-3-methylbut-2-enylamino)-7-b-D-glucopyranosylpurine]
| MW 381.39; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 38165-56-9; C16H23N5O6 | ||
 | ||
| 001 5111 | 1 | mg |
| 001 5112 | 2 | mg |
| 001 5113 | 5 | mg |
trans-ZEATIN-9-GLUCOSIDE (tZ9G) [6-((E)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-glucopyranosylpurine]
| MW 381.39; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 51255-96-0; C16H23N5O6 | ||
 | ||
| 001 0471 | 1 | mg |
| 001 0472 | 2 | mg |
| 001 0473 | 5 | mg |
trans-ZEATIN-9-GLUCURONIDE (tZ9GN)
| MW 395.38; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: NONE; C16H21N5O7 | ||
 | ||
| 001 5961 | 5 | mg |
| 001 5962 | 10 | mg |
| 001 5963 | 50 | mg |
trans-ZEATIN-O-GLUCOSIDE (tZOG) [6-((E)-4-β-D-glucopyranosyloxy-3-methylbut-2-enylamino)purine]
| MW 381.39; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 56329-06-7; C16H23N5O6 | ||
 | ||
| 001 5121 | 1 | mg |
| 001 5122 | 2 | mg |
| 001 5123 | 5 | mg |
trans-ZEATIN-O-GLUCURONIDE (tZOGN)
| MW 395.38; CRYSTALLINE; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 147663-51-2; C16H21N5O7 | ||
 | ||
| 001 5971 | 5 | mg |
| 001 5972 | 10 | mg |
| 001 5973 | 50 | mg |
trans-ZEATIN-O-GLUCOSIDE RIBOSIDE (tZROG) [6-((E)-4-β-D-glucopyranosyloxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine]
| MW 513.51; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 62512-97-4; C21H31N5O10 | ||
 | ||
| 001 5131 | 1 | mg |
| 001 5132 | 2 | mg |
| 001 5133 | 5 | mg |
trans-ZEATIN RIBOSIDE-5'-MONOPHOSPHATE SODIUM SALT (tZMP) [6-((E)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]
| MW 499.33; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 25615-16-1; C15H20N5Na2O8P.H2O | ||
 | ||
| 001 5141 | 1 | mg |
| 001 5142 | 2 | mg |
| 001 5143 | 5 | mg |
trans-ZEATIN-9-GLUCOSIDE-O-GLUCOSIDE (tZ9GOG) [6-((E)-4-β-D-glucopyranosyloxy-3-methylbut-2-enylamino)-9-β-D-glucopyranosylpurine]
| MW 543.64; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 115921-05-6; C22H33N5O11 | ||
 | ||
| 001 5501 | 1 | mg |
| 001 5502 | 2 | mg |
| 001 5503 | 5 | mg |
trans-ZEATIN-O-ACETYL (ActZ) [6-((E)-4-acetoxy-3-methylbut-2-enylamino)purine]
| MW 261.29; crystalline; purity > 98% (HPLC) | ||
| S:26, 36; CAS: 6025-82-7; C12H15N5O2 | ||
 | ||
| 001 5151 | 1 | mg |
| 001 5152 | 2 | mg |
| 001 5153 | 5 | mg |
2-CHLORO-trans-ZEATIN (2CltZ) [2-chloro-6-((E)-4-hydroxy-3-methylbut-2-enylamino)purine]
| MW 253.69; crystalline; purity > 98% (HPLC) | ||
| S:26, 36; CAS: 29736-30-9; C10H12ClN5O | ||
 | ||
| 001 5161 | 5 | mg |
| 001 5162 | 10 | mg |
| 001 5163 | 50 | mg |
2-METHYLTHIO-trans-ZEATIN (2MeStZ) [2-methylthio-6-((E)-4-hydroxy-3-methylbut-2-enylamino)purine]
| MW 265.34; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 29736-33-2; C11H15N5OS | ||
 | ||
| 001 5171 | 1 | mg |
| 001 5172 | 2 | mg |
| 001 5173 | 5 | mg |
2-METHYLTHIO-trans-ZEATIN RIBOSIDE (2MeStZR) [2-methylthio-6-((E)-4-hydroxy-3-methylbut-2-enylamino)-9-b-D-ribofuranosylpurine]
| MW 397.46; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 53274-45-6; C16H23N5O5S | ||
 | ||
| 001 5181 | 1 | mg |
| 001 5182 | 2 | mg |
| 001 5183 | 5 | mg |
cis-ZEATIN (cZ) [6-((Z)-4-hydroxy-3-methylbut-2-enylamino)purine]
| MW 219.25; crystalline; purity > 99% (HPLC) | ||
| S:26, 36; CAS: 32771-64-5; C10H13N5O | ||
 | ||
| 001 0321 | 5 | mg |
| 001 0322 | 10 | mg |
| 001 0323 | 50 | mg |
cis-ZEATIN RIBOSIDE (cZR) [6-((Z)-4-hydroxy-3-methylbut-2-enylamino)-9-b-D-ribofuranosylpurine]
| MW 351.37; crystalline; purity > 99% (HPLC) | ||
| S:26, 36; CAS: 15896-46-5; C15H21N5O5 | ||
 | ||
| 001 0331 | 5 | mg |
| 001 0332 | 10 | mg |
| 001 0333 | 50 | mg |
cis-ZEATIN-9-GLUCOSIDE (cZ9G) [6-((Z)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-glucopyranosylpurine]
| MW 381.39; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 169565-72-4; C16H23N5O6 | ||
 | ||
| 001 2891 | 1 | mg |
| 001 2892 | 2 | mg |
| 001 2893 | 5 | mg |
cis-ZEATIN-O-GLUCOSIDE (cZOG) [6-((Z)-4-β-D-glucopyranosyloxy-3-methylbut-2-enylamino)purine]
| MW 381.39; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 71866-93-8; C16H23N5O6 | ||
 | ||
| 001 3391 | 1 | mg |
| 001 3392 | 2 | mg |
| 001 3393 | 5 | mg |
cis-ZEATIN-O-GLUCOSIDE RIBOSIDE (cZROG) [6-((Z)-4-β-D-glucopyranosyloxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine]
| MW 513.51; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 125225-72-1; C21H31N5O10 | ||
 | ||
| 001 3251 | 1 | mg |
| 001 3252 | 2 | mg |
| 001 3253 | 5 | mg |
cis-ZEATIN RIBOSIDE-5'-MONOPHOSPHATE SODIUM SALT (cZMP) [6-((Z)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]
| MW 499.33; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 125225-71-0; C15H20N5Na2O8P.H2O | ||
 | ||
| 001 0591 | 1 | mg |
| 001 0592 | 2 | mg |
| 001 0593 | 5 | mg |
2-METHYLTHIO-cis-ZEATIN (2MeScZ) [2-methylthio-6-((Z)-4-hydroxy-3-methylbut-2-enylamino)purine]
| MW 265.34; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 52020-11-8; C11H15N5OS | ||
 | ||
| 001 0541 | 1 | mg |
| 001 0542 | 2 | mg |
| 001 0543 | 5 | mg |
2-METHYLTHIO-cis-ZEATIN RIBOSIDE (2MeScZR) [2-methylthio-6-((Z)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine]
| MW 397.46; crystalline; purity > 95% (HPLC) | ||
| S:26, 36; CAS: 52049-48-6; C16H23N5O5S | ||
 | ||
| 001 0561 | 1 | mg |
| 001 0562 | 2 | mg |
| 001 0563 | 5 | mg |